Plus Therapeutics Cost of Revenue 2011-2026 | PSTV

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.

What is included in the cost of revenue

Cost Category	Examples
Production Costs	Materials, wages of production staff, depreciation of equipment
Service and Support	Customer service, user support, technical assistance
Delivery and Logistics	Packaging, delivery of goods to customers
Hosting and Infrastructure	Servers, cloud platforms (especially for IT and SaaS companies)
Content and Licenses	License purchases, production royalties (e.g., in streaming services)

Importance of the Metric

Helps to understand how costly the revenue-generating process is.
A high cost of revenue may indicate:
Poor cost control
Low operational efficiency
A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Annual Cost of Revenue Plus Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	-	-	-	1.15 M	1.32 M	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.32 M	1.15 M	1.23 M

Cost of Revenue of other stocks in the Biotechnology industry

Issuer	Cost of Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	32.2 M	-	2.43 %	$ 254 M	Germany
Amphastar Pharmaceuticals AMPH	364 M	$ 19.14	0.74 %	$ 895 M	USA
Anika Therapeutics ANIK	63.6 M	$ 14.74	-0.2 %	$ 216 M	USA
AgeX Therapeutics AGE	40 K	-	-10.17 %	$ 12.2 K	USA
Autolus Therapeutics plc AUTL	96.4 M	$ 1.63	3.5 %	$ 434 M	Britain
I-Mab IMAB	27.2 M	-	-	$ 866 M	China
BioNTech SE BNTX	642 M	$ 94.9	0.82 %	$ 22.9 B	Germany
Midatech Pharma plc MTP	926 K	-	-18.52 %	$ 27.3 M	Britain
Exelixis EXEL	83.7 M	$ 49.35	2.47 %	$ 13.4 B	USA
Fortress Biotech FBIO	20.9 M	$ 2.36	-1.26 %	$ 65.8 M	USA
AbbVie ABBV	18.2 B	$ 203.32	0.97 %	$ 360 B	USA
Gilead Sciences GILD	6.23 B	$ 133.2	1.42 %	$ 166 B	USA
Compugen Ltd. CGEN	9.25 M	$ 2.82	-2.76 %	$ 263 M	Israel
Enlivex Therapeutics Ltd. ENLV	737 K	$ 0.77	0.16 %	$ 35.2 M	Israel
ACADIA Pharmaceuticals ACAD	81.8 M	$ 22.41	0.04 %	$ 3.71 B	USA
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	4.85 M	-	5.93 %	$ 314 M	Canada
Grifols, S.A. GRFS	4.42 B	$ 8.05	-0.62 %	$ 5.47 B	Spain
CureVac N.V. CVAC	238 M	-	-	$ 867 M	Germany
AIkido Pharma AIKI	145 M	-	1.93 %	$ 17.4 M	USA
Albireo Pharma ALBO	1.36 M	-	-0.23 %	$ 916 M	USA
Arcutis Biotherapeutics ARQT	36.7 M	$ 21.09	-0.4 %	$ 2.68 B	USA
Ampio Pharmaceuticals AMPE	369 K	-	-11.43 %	$ 502 K	USA